The US Food and Drug Administration has approved
daraxonrasib, sold as Rasonque, for
certain adults with metastatic pancreatic adenocarcinoma. The once-daily
tablet is the first approved medicine designed to broadly inhibit active
RAS proteins—molecular switches that drive most pancreatic cancers and
resisted drug development for decades.
The decision is backed by a randomized Phase 3 trial involving 500
adults. Median overall survival was 13.2 months with daraxonrasib and
6.7 months with standard chemotherapy. That is a major result in a
disease where effective later-line options have been limited, but it
does not mean the drug cures pancreatic cancer or that every patient
will live twice as long.
The
FDA approved the drug on 26 August 2026 for adults whose pancreatic
adenocarcinoma has spread to other parts of the body and who have either
received at least one previous systemic treatment or cannot receive a
multi-drug systemic regimen.
Why RAS has been such
a difficult target
RAS proteins sit near the top of signalling networks that tell cells
when to grow and divide. In a healthy cell, RAS cycles between inactive
and active states. Cancer-associated mutations—most often in the
KRAS gene in pancreatic cancer—can leave the signal
abnormally active, encouraging uncontrolled growth.
More than 90% of pancreatic cancers carry a cancer-driving KRAS
mutation, according to the Dana-Farber
Cancer Institute’s explanation of the trial. Yet RAS was long
described as “undruggable.” Its surface does not offer the deep, stable
pockets that conventional small-molecule medicines often use as docking
sites, and the protein binds its natural partners extremely tightly.
Recent medicines have succeeded against particular KRAS mutations,
but pancreatic tumours contain several different RAS variants.
Daraxonrasib takes a broader approach. It binds the active, or
“RAS(ON),” form of multiple RAS proteins by recruiting another protein
called cyclophilin A. The resulting complex blocks RAS from passing
growth signals onward.
This “molecular glue” mechanism is important because the medicine is
not restricted to a single KRAS variant. The FDA’s indication also does
not require a particular RAS mutation test result.
Daraxonrasib trial: survival and tumour response
The international RASolute 302 trial randomly
assigned 500 adults with previously treated metastatic pancreatic
adenocarcinoma to daraxonrasib or a physician-selected standard
chemotherapy. It was an open-label trial, meaning participants and
clinicians knew which treatment was given, although tumour scans used
for key assessments were reviewed centrally.
The peer-reviewed
study in the New England Journal of Medicine reported three clear
advantages for daraxonrasib in the overall study population:
- Median overall survival: 13.2 months with
daraxonrasib versus 6.7 months with chemotherapy. - Median progression-free survival: 7.2 months versus
3.6 months. - Objective response rate: 30% versus 11% in the
FDA’s analysis.
The hazard ratio for death was 0.40. In plain language, the
daraxonrasib group experienced a substantially lower rate of death over
the study’s follow-up period. A hazard ratio is not the same as saying
each individual’s lifespan doubled, and median survival describes the
point at which half the group remained alive—not a prediction for a
particular person.
The trial is registered as NCT06625320 on
ClinicalTrials.gov. It compared daraxonrasib with accepted
later-line chemotherapy, making the survival difference more informative
than results from a single-arm study without a control group.
Who is covered by the FDA approval?
The FDA approval is not for every person with pancreatic cancer. It
covers adults with metastatic pancreatic adenocarcinoma
who have already received at least one systemic treatment, or who are
not candidates for multiagent therapy.
It does not establish daraxonrasib as a preventive treatment, a
therapy for localized disease or a universal first-line replacement for
chemotherapy. A separate Phase 3 program is evaluating the drug—with or
without chemotherapy—in previously untreated metastatic disease.
The distinction matters because headlines about “pancreatic cancer”
can obscure several different diseases and treatment stages. Pancreatic
adenocarcinoma is the commonest type, but neuroendocrine tumours and
other uncommon pancreatic cancers have different biology and treatment
pathways.
Side effects still matter
Targeted does not mean harmless. The FDA lists rash, diarrhoea,
inflammation of the mouth, nausea, fatigue, vomiting, abdominal pain,
swelling, reduced appetite and bleeding among the most common adverse
effects.
The prescribing information also carries warnings about serious skin
and soft-tissue toxicity, gastrointestinal perforation, interstitial
lung disease or pneumonitis, and embryo-fetal toxicity. These risks
require clinical monitoring and can make treatment unsuitable for some
people.
The trial’s open-label design can influence subjective outcomes such
as symptom reporting. Overall survival is less vulnerable to that bias,
however, and the magnitude of the randomized survival result is the
central reason this approval is significant.
Why the decision
matters beyond one drug
Daraxonrasib marks a change in what cancer drug developers can
attempt. Instead of targeting only one uncommon KRAS mutation, it shows
that a medicine can interfere with several active RAS forms and produce
a survival benefit in a large randomized trial.
That does not guarantee success in other RAS-driven tumours.
Different cancers have different surrounding biology, resistance
mechanisms and treatment histories. But lung and colorectal cancers also
frequently contain RAS alterations, and broad RAS inhibitors are being
tested across several tumour types.
The regulatory process is also notable. The FDA used Priority Review,
Real-Time Oncology Review and Project Orbis, working alongside Health
Canada while European and Japanese regulators observed. The
agency says the US decision arrived approximately 6.5 months ahead of
its goal date. Faster review does not mean the Phase 3 evidence was
skipped; the randomized trial supplied the efficacy basis for the
decision.
The evidence-led conclusion
Daraxonrasib is not a cure for metastatic pancreatic cancer. Even in
the successful trial, the disease eventually progressed in many
participants, and the drug can cause serious adverse effects.
What changed is narrower and still consequential: a once-daily drug
aimed at active RAS proteins improved overall survival, progression-free
survival and tumour response compared with standard later-line
chemotherapy in a 500-person randomized Phase 3 trial. The FDA has now
converted that evidence into an approved option for a clearly defined
group of patients.
For a target once treated as almost beyond the reach of medicines,
that is a genuine biotechnology milestone.
Reporting note
This article reports an FDA approval supported by a peer-reviewed,
randomized Phase 3 trial. The trial was open-label and funded by
Revolution Medicines, the drug’s developer. The FDA indication is
limited to adults with metastatic pancreatic adenocarcinoma who have
received previous systemic therapy or are not candidates for multiagent
systemic therapy. Approval in the United States does not automatically
mean approval in other countries.
Sources and further reading
- FDA
oncology approval notice: efficacy, safety and indication - FDA
press announcement, 26 August 2026 - New
England Journal of Medicine: RASolute 302 Phase 3 trial - PubMed record
for the peer-reviewed trial - ClinicalTrials.gov
registration: NCT06625320 - Dana-Farber
Cancer Institute: trial results and RAS mechanism - European
Medicines Agency: accelerated assessment in Europe
FutureTechDose covers biotechnology, AI, data-centre and
energy-sector research and industry progress for a general audience.
This article is informational and does not provide medical or investment
advice.
Leave a Reply